Wnt/β-catenin-IN-6
Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun) . Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research[1].
Product Specifications
UNSPSC
12352211
Target
Akt; Apoptosis; c-Myc; COX; EGFR; ERK; GSK-3; Interleukin Related; JNK; Wnt; β-catenin
Related Pathways
Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Purity
98.34
Solubility
DMSO : 5.83 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
COC1=C(OCC2=CC=CC=C2)C=C(N=CN=C3NC4=CC=C(NC(C=C)=O)C=C4)C3=C1
Molecular Formula
C25H22N4O3
Molecular Weight
426.47
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt; COX-2; EGFR/ErbB1/HER1; ERK; GSK-3β; IL-8; JNK
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (DF1485), CF647 conjugate, 0.1mg/mL
P27 / KIP1 (SX53G8), CF740 conjugate, 0.1mg/mL
CD45 / LCA (2B11 + PD7/26), CF647 conjugate, 0.1mg/mL
Glycophorin A / CD235a (Erythrocyte Marker) (rGYPA/280), CF488A conjugate, 0.1mg/mL
